Ribon Therapeutics has commenced the healthy volunteer segment of its first-in-human Phase I clinical trial to analyse the potential of its oral therapy, RBN-3143, to treat atopic dermatitis.

A poly (ADP-ribose) polymerase family member 14 (PARP14) inhibitor, RBN-3143 could be used to treat various inflammatory diseases.

Expressed in tissues of inflammatory diseases, PARP14 facilitates the inflammatory cells infiltration such as eosinophils and neutrophils, the decline of which could have advantages over existing treatments.

Selectively hindering PARP14 causes a decline in alarmins and IL-17 and IL-4/13 signalling pathway dampening. 

The single ascending dose and multiple ascending dose trial will analyse the safety and pharmacokinetics of RBN-3143.

Ribon Therapeutics president and CEO Prakash Raman said: “The news of the initiation of RBN-3143, our second programme to move into the clinic, is an important advancement for Ribon that broadens our Company’s portfolio to now include first-in-class programmes in both oncology and inflammatory diseases, leveraging our pioneering research in the role of NAD+-utilising enzymes in stress support pathways. 

“As a first-in-class, oral small molecule inhibitor of PARP14, RBN-3143 has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases.”

Apart from RBN-3143, the portfolio of the company comprises another first-in-class clinical programme, RBN-2397, targeting various indications in oncology and inflammatory diseases.

In July last year, Ribon raised $65m in a funding round led by Deerfield Management and US Venture Partners.

New investors Avego Bioscience Capital, GV, Monashee Investment Management and Peregrine Ventures also took part in the financing round.

The funds were used to advance the clinical development of its precision treatment candidates.